Interleukin-31 pathway and its role in atopic dermatitis: a systematic review

Autor:	Elias Oussedik, Steven R. Feldman, Mohammed D. Saleem, Veronica D’Amber
Rok vydání:	2017
Předmět:	0301 basic medicine medicine.medical_specialty Eczema Lifetime prevalence MEDLINE Dermatology Antibodies Monoclonal Humanized Chronic inflammatory disease Dermatitis Atopic 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Key terms Quality of life Anti-Allergic Agents medicine Animals Humans Clinical Trials as Topic business.industry Interleukins Pruritus Receptors Interleukin Atopic dermatitis Immunoglobulin E medicine.disease body regions Clinical trial 030104 developmental biology Interleukin 31 Immunology business
Zdroj:	Journal of Dermatological Treatment. 28:591-599
ISSN:	1471-1753 0954-6634
DOI:	10.1080/09546634.2017.1290205
Popis:	Atopic dermatitis, a chronic inflammatory disease, has a lifetime prevalence of 10-20%. Atopic dermatitis reduces quality of life, primarily due to pruritus. Interleukin-31 and its target receptor are newly discovered entities that are involved in pruritus.To summarize the current understanding of interleukin-31 and its role in atopic dermatitis, potential therapeutic interventions and future prospects.A systematic review was designed to identify articles related to interleukin-31 and its role in pruritus. Predefined queries containing interleukin-31 and related key terms were searched with no past date restriction, through 31 August 2016, using MEDLINE, Cochrane Controlled Trials Register, ClinicalTrials.gov and the International Clinical Trials Registry Platform Search Portal database.Of 151 identified articles, 61 met eligibility criteria. Interleukin-31 receptors are expressed constitutively on the surface of keratinocytes, eosinophils and small diameter neurons. Overexpression of interleukin-31, independent of mast cells and lymphocytes, induces clinical and histological features consistent with atopic dermatitis. In addition, overexpression of interleukin-31 causes reversible alopecia. Human monoclonal interleukin-31 antagonist, CIM331, decreased pruritus in phase-I and phase-II clinical trials.Interleukin-31 plays an important role in atopic dermatitis and alopecia. Inhibiting this pathway may provide an alternative to antihistamines for the pruritus of atopic dermatitis.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391aa03ee75ddfcb1501cde23c983977 https://doi.org/10.1080/09546634.2017.1290205 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.